Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR19.20.22 in Relapsed/Refractory B-Cell Lymphomas
NCT07168486Phase 1Enrolling by invitation
- Sponsor
- University of Maryland, Baltimore
- Start
- Oct 2024
- Primary completion
- Jul 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CAR19.20.22 in B cell lymphoma (3 arms), sponsored by University of Maryland, Baltimore. Primary endpoints: Treatment-related adverse events at 24 months, Overall Response Rate at 24 months and 2 more. Started Oct 2024; status: enrolling by invitation.
02
Drugs
CAR19.20.22
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT07168486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07168486.